Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 13,701–13,800 of 15,747
Blattner, M., Schäfer, I., Nestoriuc, Y., Büchel, C., Scherer, M., & Oltrogge, J. H. (2026) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.70372
Responses against infectious disease pandemics: a narrative review on COVID-19
Chung, D. R. (2021) · Precision and Future Medicine · doi:10.23838/pfm.2021.00156
“(WHO) and later declared a pandemic [51].”
Ye, T., Alamgir, A., Robertus, C. M., Colina, D., Monticello, C., Donahue, T. C., Hong, L., Vincoff, S., Goel, S., Fekkes, P., et al. (2026) · Science Advances · doi:10.1126/sciadv.aec8271 · Cited by 9
COVID-19 – One Virus, One World But Different Vaccines and ShotsPreprint
Sok, P. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3925477
Cruz, J., Harwood, R., Kenny, S. E., Clark, M. P. A., Davis, P. J., Draper, E. S., Hargreaves, D. S., Ladhani, S. N., Luyt, K., Turner, S., et al. (2024) · Archives of Disease in Childhood · doi:10.1136/archdischild-2024-327293
Earnest, L., Fernandez‐Ruiz, D., Edeling, M. A., Montoya, J. C., Yap, A. H. Y., Wong, C. Y., Holz, L. E., Gras, S., Cooney, J. P., Davidson, K. C., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4771359
Barilan, Y. M., Brusa, M., & Ciechanover, A. J. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780198863465.002.0003
Rughiniş, C., Dima, M., Vulpe, S., Rughinis, R. V., & Vasile, S. (2023) · Public Health in Practice · doi:10.1016/j.puhip.2023.100416
Google Trends Analysis of Otologic Symptom Searches Following COVID-19.
Kim, J. K., Tawk, K., Kim, J. M., Djalilian, H. R., & Abouzari, M. (2024) · PubMed Central · doi:10.22038/ijorl.2024.75617.3532
Mercadé‐Besora, N., Raventós, B., Trinh, N. T., Li, H., Hayati, S., Giuliodori, A., Burkard, T., Burn, E., Català, M., Prieto‐Alhambra, D., et al. (2025) · medRxiv · doi:10.1101/2025.05.16.25327593
New age in vaccinology: the impact of the COVID-19 pandemic on third-generation vaccine development
Ramos, E. L. P., Vedova-Costa, J. M. D., Pacce, V. D., Ferreira, G. N., Guzmán, Y. C. M., Boschero, R. A., Hospinal-Santiani, M., & Thomaz‐Soccol, V. (2021) · Biotechnology Research and Innovation · doi:10.4322/biori.202103
Eren, O. E., Tonon, M., Schöberl, F., et al. (2021) · Infection · doi:10.1007/s15010-021-01613-w
Seroprevalence in Argentinian healthcare workers after vaccination with Sputnik V
Santonato, D., Malvicini, M. A., Novau, A., et al. (2022) · International journal of infection control · doi:10.3396/ijic.v18.21791
Research progress and future perspectives on in vivo CAR-T vector delivery technology
Yu, K., & Zhen-Kun, W. A. N. G. (2026) · Shengming kexue · doi:10.3724/cbls.2026068
Single-cycle SARS-CoV-2 vaccine elicits high protection and sterilizing immunity in hamstersPreprint
Lett, M. J., Otte, F., Hauser, D., Schön, J., Kipfer, E. T., Hoffmann, D., Halwe, N. J., Ulrich, L., Zhang, Y., Cmiljanović, V., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.17.541127 · Cited by 2
“…countries, causing symptoms and COVID-19 disease, despite an unprecedented, quick deployment of effective first-generation mRNA-and vector-based vaccines (Baden et al., 2021; Beesley et al., 2023; Polack et al., 2020; Sadoff et al., 2022; Voysey et al., 2021), targeting the viral Spike (S) protein.”
BackgroundLong-Term Duration of Antibody Response to SARS CoV-2 in One of the Largest Slums of Buenos AiresPreprint
Pagotto, V. L., Luna, L., Salto, J., Manslau, M. W., Figar, S., Mistchenko, A. S., Carciofi, G., Weinberger, N., COVIDAR Group, Saldaño, A. M. G., et al. (2021) · medRxiv · doi:10.1101/2021.03.05.21253010
Humoral immune response and safety of Sars-Cov-2 vaccine in people with multiple sclerosis
Hamzavi, S. S., Bahrololoom, R., Saeb, S., Marandi, N. H., Hosseini, M., Abadi, A. K. H., & Jamalidoust, M. (2024) · BMC Immunology · doi:10.1186/s12865-024-00628-w · Cited by 1
Lacoux, C., Villes, V., Riegel, L., Coulmain, S., Lorente, N., Derras, S. E., Castro, D. R., Roux, P., Delabre, R. M., & Michels, D. (2024) · Harm Reduction Journal · doi:10.1186/s12954-024-01096-6
“In Europe, the first vaccine to obtain marketing authorization was Comirnarty (Pfizer & BioNTech) in December 2020 followed by Jcovden (Janssen), Spikevax (Moderna), and others [3–5].”
BackgroundPeptide-Based Complex Coacervates Stabilized by Cation-π Interactions for Cell EngineeringPreprint
Sun, Y., Wu, X. J., Li, J., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.20.619264
Vaccination against COVID-19 and pregnancy
Veček, N., Blažić, T. N., Nonković, D., Arch-Veček, B., & Mihaljević, S. (2022) · Liječnički vjesnik · doi:10.26800/lv-144-9-10-6
Mining antibody functionality via AI-guided structural landscape profiling
Terekhov, S. S., Ivanisenko, N. V., Zhang, N., Mokrushina, Y. A., Nolde, D. E., Lomakin, Y. A., Zalevsky, A. O., Ovchinnikova, L. A., Malabuiok, D. M., Baranova, M. N., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-70553-6
mRNA-Based Designer APCs Elicit Robust CD8⁺ and CD4⁺ T Cell ResponsesPreprint
Le, T. V., Imai, S., Fujitsuka, I., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.16.676697
Ateş, H., & Şahiner, E. S. (2022) · Çocuk Enfeksiyon Dergisi/Journal of Pediatric Infection · doi:10.5578/ced.20229754
“While adverse reactions in inactivated vaccines are usually local and non-serious, adverse reactions in vaccines produced with new techniques cause systemic and serious adverse reactions (14,15).”
BackgroundCOVID-19 vaccine safety in adults: A narrative review of adverse reactions in ASEAN countries
Andini, P., Darmawan, E., Muflih, A., & Ridwan, M. (2026) · Scripta Medica · doi:10.5937/scriptamed57-60151
Odhar, H. A. (2023) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/q4u5d
Holtkamp, C., Schöler, L., Anastasiou, O. E., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4087986
Étude de la réponse humorale lors de l'infection par le SARS-CoV-2
Marot, S. (2023) · theses.fr (ABES) · doi:10.70675/7d41e61azd818z408dzb17cz1c0cf0738b83
Perspective Chapter: Liposome Mediated Delivery of Immunotherapeutics for Cancer
Iscaro, A., Howard, F. H. N., Yang, Z., Jenkins, F., & Muthana, M. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.108282 · Cited by 1
Imren, K. U. R. T. (2022) · Journal of Clinical Case Studies Reviews & Reports · doi:10.47363/jccsr/2021(4)204
Monoclonal antibody for COVID-19: Unveiling the recipe of a new cocktail
Bajpai, J., Kant, S., Verma, A. K., & Pradhan, A. K. (2023) · World Journal of Respirology · doi:10.5320/wjr.v12.i1.1
Coupled carrier-message engineering for low-dose mRNA vaccination
Xu, J., Kim, J. G., Song, J., et al. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.103009
Hwang, J. K., Dzimitrowicz, H. E., Shah, R., et al. (2021) · Regular and Young Investigator Award Abstracts · doi:10.1136/jitc-2021-sitc2021.625
Marklund, E., Leach, S., Nyström, K., Albertsson, A.-M., Li, Y., Yilmaz, A., Andersson, L., Bemark, M., Lundgren, A., & Gisslén, M. (2026) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2026.2624526
Exacerbation of Chronic Obstructive Pulmonary Disease during Outbreak Pandemic
Rohmah, U. N., Rosliany, N., & Suarti, N. M. (2022) · The Journal of Palembang Nursing Studies · doi:10.55048/jpns.v1i2.19
The history of pandemics and epidemiological modeling
Lazebnik, T. (2026) · Elsevier eBooks · doi:10.1016/b978-0-44-355525-1.00007-2
SARS-CoV-2 Infection after Vaccination in Health Care Workers: Case Series
Giwangkancana, G. W., Hartantri, Y., Rais, R., & Permatasari, T. S. A. A. (2021) · doi:10.29011/2575-9760.001411
Jogi, M. K., Shikha, S., Singh, P., Sharma, D., Shreyansh, S., Mishra, P., Priyadarsini, A., Priyadarsini, A., Choudhary, D. K., Jain, M., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1846973
Peña-Galo, E. M., Alcaine, J. M. T., Gracia-Carrasco, E., & Alcedo-González, J. (2021) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2021.01.004
Metal nanoparticles: Biosynthesis to applications (Review)
Verma, R., Kala, A., Aziz, R. B., Saxena, R., Gaurav, N., Rawat, B. S., & Rautela, I. (2026) · World Academy of Sciences Journal · doi:10.3892/wasj.2026.440
Legal Framework for the Design and Construction of COVID Hospitals in the Russian Federation
Sitdikova, G. Z., Lifanova, M. V., & Kornelyuk, O. V. (2022) · Lecture notes in civil engineering · doi:10.1007/978-3-030-99877-6_26
Ali, S., Macias, K. C., Mathias, J. V., et al. (2024) · Annals of Internal Medicine Clinical Cases · doi:10.7326/aimcc.2023.0652
Mahjabeen, N. (2025) · European Journal of Medical and Health Sciences · doi:10.24018/ejmed.2025.7.4.2355
Porcentaje de aplicación primeras y únicas dosis por grupo etario contra SARS-CoV-2 en Colombia
Pinzón, J. E. D. (2023) · Revista de Investigaciones Universidad del Quindío · doi:10.33975/riuq.vol35ns1.816
Shaping social attitudes towards vaccination against COVID-19 and social assistance
Pilarska, N. (2021) · Praca Socjalna · doi:10.5604/01.3001.0015.5795
Jiang, M., Akers, N. K., Gill, D. B., Eckhert, B., Svejnoha, E., & Robins, H. S. (2022) · medRxiv · doi:10.1101/2022.07.01.22277108
Tuba, S., Widyati, Sulaiman, S. A. S., & Hasibuan, A. K. H. (2022) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2022.1010003 · Cited by 1
Georgieva, M. V., Sun, T., & Beck, E. C. (2024) · Infectious Diseases and Therapy · doi:10.1007/s40121-024-01039-5
“The pivotal clinical trials evaluating the safety and efficacy of the two mRNA COVID-19 vaccines excluded people with immunocompromising conditions and those prescribed immune-modifying therapies [2, 3].”
BackgroundEffect of Vaccination on Long-COVID: A Comprehensive Review and Approach
Frank, H. (2023) · International Journal of Medicine and Public Health · doi:10.5530/ijmedph.2023.1.1
Journal update monthly top five
Reynard, C., Prager, G., Oliver, G. J., Jafar, A. J. N., Naguib, M. P., Body, R. M., & Carley, S. D. (2021) · Emergency Medicine Journal · doi:10.1136/emermed-2021-212053 · Cited by 1
Yeo, J., Yun, M.-R., Kim, S.-Y., Seok, J.-H., Jeon, J. H., Lee, T., Kim, J., Kim, K., Park, M., Kim, D., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1718740
Acacetin-incorporated lipid nanoparticles for inhaled mRNA vaccines
Huang, X., Fan, K., Zhang, Y., Yang, Y., Wang, Y., Yang, X., Meng, Z., Guo, Q., Li, Y., Gong, N., et al. (2026) · Nanoscale Horizons · doi:10.1039/d5nh00794a
Dueker, K., Capozzola, T., Feng, Z., Lin, R. N., Hurtado, J., Bangaru, S., Yuan, M., Beutler, N., Garcia, E., He, W.-T., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.22.700386
R, S. K. D., Srividya, J., Patel, A. E., & Ramesh, V. (2022) · European journal of health research · doi:10.32457/ejhr.v8i1.1786 · Cited by 5
Diyantoro, Rantam, F. A., Juniastuti, Wijaya, A. Y., Susilowati, H., Kuncorojakti, S., & Aswin, A. (2026) · Heliyon · doi:10.1016/j.heliyon.2026.e44788
Lee, F.-S. W., Wang, J., & Wang, C.-H. J. (2022) · Research Square · doi:10.21203/rs.3.rs-1548194/v1
Um, H., Kim, S., Wang, S. X., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.5046882
Luca, A. R., Teiu, R. E., Ursuleanu, T. F., Grigorovici, R., Hlescu, C. S., Comanescu, M. P., Calin, A. I., & Grigorovici, A. (2024) · Romanian Journal of Oral Rehabilitation · doi:10.62610/rjor.2024.4.16.83
Rabbani, S. A., Sharma, S., Mishra, S., & Mahtab, A. (2021) · Journal of Pharmaceutical Research International · doi:10.9734/jpri/2021/v33i24b31445
“The phase 3 randomized placebocontrolled trial of this vaccine conducted 43,448 participants showed that a two-dose regimen (doses given 21 days apart) conferred 95% protection against COVID-19 with no safety concerns [79].”
BackgroundSchoepf, I. C., Riebensahm, C., Becchetti, C., Blaser, V., Unternährer, C. V., Banz, V. M., Hirzel, C., Suter‐Riniker, F., & Berzigotti, A. (2023) · Swiss Medical Weekly · doi:10.57187/smw.2023.40118
Cheli, B., Bellavite, P., Foschi, R., Bagnato, A., Gregori, M., Trambusti, G., & Donzelli, A. (2026) · F1000Research · doi:10.12688/f1000research.181425.1
Alzahrani, W. M. (2023) · Cardiometry · doi:10.18137/cardiometry.2023.26.168176 · Cited by 1
COVID-19 mRNA vaccines and their applications in chronic liver diseases
Zhu, J. (2021) · Canadian Liver Journal · doi:10.3138/canlivj-2020-0001
Bosinger, S. E., Edwards, C. T., Karunakaran, K. A., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.07.30.605768
Lescura, N. I., Selent, C., Guerci, M. N., Bertachini, O., López, M. V., de Prada, A. M., Fernández, M. D. V., Barboza, N. V., Juárez, M. D. V., Cáceres, A. F., et al. (2024) · Revista Panamericana de Salud Pública · doi:10.26633/rpsp.2024.94
COVID-19 Vaccination Issues in Solid Organ Transplant Recipients
Parabina, E. V., Konstantinov, D. Y., Kaabak, M. M., Rappoport, N. N., Pushkin, S. Y., Selyutin, A. A., Navasardyan, А. S., Владиславовна, М. У., Alexandrova, V. E., & Yaremin, B. I. (2021) · Bulletin of the Medical Institute REAVIZ (REHABILITATION DOCTOR AND HEALTH) · doi:10.20340/vmi-rvz.2021.4.covid.2
Prévention des infections et vaccination dans les rhumatismes inflammatoires chroniques
Morel, J. (2022) · Revue du Rhumatisme Monographies · doi:10.1016/j.monrhu.2022.07.004
Systematic Modulation of the Lipid Composition Enables to Tune Liposome Cellular Uptake PathwaysPreprint
Mateos‐Maroto, A., Gai, M., Brückner, M., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4160452
Kuczkowska, K., Bjerkan, L., Stubsrud, E., Husbyn, H., Chellappa, S., Hauge, A., Skarshaug, R., Torgersen, M. L., Heim, J. B., Jørgensen, M. J., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-46223-8 · Cited by 1
“As spike mRNA vaccines against SARS-CoV-2 can protect against severe disease around 10 days after vaccination 40, 41 , in contrast to neutralizing antibodies that are detectable after day 21 42, 43 , CD8 + T cells have been suggested as mediators of protection at this early stage 44 .”
BackgroundCOVID-19 immunization in people with cancer—Is it safe and efficient? What do we know?
Lazăr, D. E., & Munteanu, A. (2022) · Tumori Journal · doi:10.1177/03008916221090544
Xia, Q., O’Grady, K.-A. F., Vardon, P., Ward, S. R., Gregory, R., Davies, J. M., & Carter, H. E. (2025) · Vaccines · doi:10.3390/vaccines13070712
“These events are typically transient and self-limiting, and they are considered a normal immune response to vaccination [4].”
InfluentialPepin, K. (2022) · Digital Commons - URI (University of Rhode Island) · doi:10.23860/diss-pepin-kristen-2022 · Cited by 2
Manzi, S., Lindholm, C., Hupka, I., Zhang, L. (., Shroff, M., Abreu, G., Werther, S., & Tummala, R. (2022) · Lupus Science & Medicine · doi:10.1136/lupus-2022-lupus21century.28
Advancements in Clinical Research: Phases, Ethical Considerations, and Technological Innovations
Ashish, P. (2024) · Archives of Case Reports · doi:10.29328/journal.acr.1001102
Nguyen, C. M., Luong, B. A., Tran, T. T., Nguyen, H., & Tran, L. S. (2023) · Future Virology · doi:10.2217/fvl-2023-0066
A Comparative Review of mRNA, Viral Vector, Inactivated, and Protein Subunit COVID-19 Vaccines
Payal, G., Vaishnavi, J., & Sunil, R. (2025) · International Journal of Community Pharmacy · doi:10.65301/ijcp.2025.6.2.5
Central diabetes insipidus following COVID-19 mRNA vaccination: a case report
Kim, M., Hahm, J. R., Jung, J., Jung, J. H., Kim, K. Y., Kim, H., Baek, J. H., Shin, H. S., Kang, K. R., & Kim, S. K. (2023) · Kosin Medical Journal · doi:10.7180/kmj.23.105
Wong, I. C. K., Lam, I. C. H., Zhang, R., Man, K. K. C., Wong, C. K. H., Chui, C. S. L., Lai, F. T. T., Li, X., Chan, E. W., Lau, C. S., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3291909/v1
Viral Infections: Overview with a focus on Prevention of Transmission
Wong, S., Chiu, K. H., Yip, C. C., Chan, J. F., Hung, I. F., To, K. K., Cheng, V. C., & Yuen, K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99967-0.00208-8
Fantin, R., Das, S., Loría, V., Calderón, A., Aparicio, A., Youn, J.-H., Lee, O., Barahona-Ordonez, J., Porras, C., Herrero, R., et al. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.128506
Ali, M., Brady, M., Campbell, P., Rooney, S., Williams, L. J., Paul, L., Mason, H., Manoukian, S., Chung, C. S., Barber, M., et al. (2026) · Health and Social Care Delivery Research · doi:10.3310/gjma0602 · Cited by 1
Li, Y., Guo, T., Zhong, J., Fang, C., Xiong, H., Hu, Z., Zhu, Y., Tan, J., Liu, S., Jing, Q., et al. (2022) · Vaccines · doi:10.3390/vaccines10111855
“Several studies [4,31] have shown that vaccine effectiveness decreases as antibody levels decline.”
BackgroundCOVID-19 preventive behavior and associated factors in nursing students
Cortes, A. P. F., Cortes, V. F., Lucena, O. L., et al. (2025) · Revista gaúcha de enfermagem · doi:10.1590/1983-1447.2025.20240221.en
Noguchi, K. S., Nguyen, L., Mehdipour, A., Wiley, E., Saunders, S., Moncion, K., Reid, J. C., Bakaa, N., Díaz, L. G., Damme, J. V., et al. (2022) · Frontiers in Rehabilitation Sciences · doi:10.3389/fresc.2022.881606 · Cited by 1
“Three key research challenges and corresponding strategies emerged, including (1) pandemic protocol adjustments, (2) participant accessibility, and (3) knowledge dissemination.”
BackgroundInfluentialAnanyev, M., Poyker, M., & Tian, Y. (2022) · Springer eBooks · doi:10.1007/978-3-319-57365-6_329-1 · Cited by 1
Causation and Classification of Disease
Fuller, J. (2025) · Oxford University Press eBooks · doi:10.1093/9780190066178.003.0005
Shioda, T. (2026) · Springer eBooks · doi:10.1007/978-981-95-6378-4_2
Nucleic acid-based immune checkpoint blockade: Progress and potential
Walters, A. A., Dhadwar, B., & Al‐Jamal, K. T. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85781-9.00011-7
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.